

INDEX

- Acceptor sites, 235, 236
Acetic acid-induced urinary bladder pain, 82
Adenine nucleotide transporter (ANT), 159
Adenosine diphosphate (ADP), 156
Adrenal gland, 325
AHP, 197, 198
 amplitude, 198
A-kinase anchoring proteins (AKAPs), 283
Aldo-keto reductase enzymes, 133
Alzheimer's disease, 15, 160
Amino acid residues, 136
Amino acid sequences, 129, 157
Amino-terminal cytoplasmic domain, 345
AMP, 429
 dependent protein kinase, 281
Amphibian neurons, 402
Amphipathic helices, 163
Amyloid precursor protein (APP), 15
Angiotensin stimulation, 305
Anomalous rectifier, 262
Anoxia-sensitive neurons, 254
ANT, 175
Antiapoptotic proteins, 166
 BCL-2, 166
 BCL-xL, 166
Anticonvulsant compounds, 375
 zonisamide, 375
Antiepileptic compounds, 209
Antiepileptic drug, *see* Ethosuximide
Antiepileptic drugs, 44, 397
Antihyperalgesic effects, 43
Antisense oligonucleotides, 43
AP firing, 292
Apoptosis, 160
Apoptosis channel, 161
Apoptotic pathways, 258
Apoptotic stimuli, 182
 growth factor deprivation, 182
Arginine residues, 6
Arterial smooth muscle cells, 259
Aspartic acid, 332
ATP, 155, 179, 183, 258, 267
 binding motif, 204
 injection, 181
 production, 170
 regulated K⁺ channels, 265
Automated electrophysiology
 systems, 454

- Automated single-cell electrophysiology, 453
- Automated tissue-based electrophysiology, 457
- Auxiliary calcium channel subunits, 223
- Axon Instruments, 455
- B-adrenergic receptors, 283
- B-cell lymphomas, 161
- B interaction domain (BID), 7
- BAD, 170
- pathological roles, 170
 - physiological roles, 170
- Basolateral amygdala neurons, 130
- Bax channels, 167
- BCL-2 family proteins, 156, 176, 162, 183, 268
- BCL-xL injection, 182
- BCL-xL interaction, 168
- BCL-xL protein, 181
- Bepidil, 206, 207
- BFNC, 399
- Binaural pathway, 198
- Binding partners, 162
- Biochemical measurements, 303
- Bithionol, 207, 208
- BK blockers, 435
- BK channel(s), 260, 317, 427, 430, 432, 435
- BK channel blockers, 436
- BK channel inhibitors, 108, 109, 110
- BK channel protein, 118
- BK channel regulation, 423
- BK_{Ca} channels, 200, 202, 203
- Blood-brain barrier, 45
- BMS-204352, 405–406
- Bongkrekic acid, 175
- Bradykinin-induced pain, 44
- Bristol-Myers Squibb (BMS) compounds, 410
- BTX binding, 376
- C-terminal fragment, 9
- C-terminus isoforms, 230
- Ca²⁺-activated K⁺ currents/channel, 197, 200
- Calcium-activated potassium, 423
- channels, 220
- Calcium-dependent inactivation, 9
- Calcium-selective channel, 171
- Calcium-selective current, 173
- Calcium channel antagonists, 3
- nifedipine, 3
- Calcium channel-associated transcription regulator (CCAT), 9, 19
- Calcium channel binding, 7
- Calcium channels, 4, 15
- discovery, 4
 - history, 4
 - involvement of, 15
- Calcium homeostasis, 171
- Calcium phosphate complex, 171
- Calcium signaling, 21
- Canine pulmonary arteries, 260
- Capsaicin assay, 45
- Cardiac long-QT syndrome, 395
- Cardiac muscle disorders, 20
- Cardiovascular disorders, 6
- Carrageenan-induced inflammation, 82
- cDNA library, 199, 395
- Cell adhesion molecule, 76
- Cell membrane, 67
- depolarization of, 67
- Cell-specific factors, 223
- Cell surface expression levels, 138
- Cellular processes, 155
- Cellular proteins, 161
- Central nervous system (CNS), 8, 39, 196, 251, 395
- therapeutics, 426
 - tumors, 106
- Cerebellar basket cell synaptic terminals, 143
- Cerebellar granule cells, 132
- CFA injection, 83
- CGMP-dependent protein kinase, 324
- Charge carriers, 196
- Chemically induced dimerization (CID), 297
- Chemotherapeutic agents, 116
- Childhood absence epilepsy (CAE), 50
- Chinese hamster ovary (CHO) cells, 201, 206, 295
- Chronic cardiopulmonary diseases, 256
- Chronic constriction injury (CCI), 78
- Chronic hypoxia, 256
- Chronic nerve injury model, 378
- Chronic pain, 366

- Chronic pain syndromes, 72
 CIC channels, 112
 CNS-penetrant compounds, 47
 CNS cell differentiation, 262
 CNS diseases, 22
 CNS distribution, 41
 Cognition-enhancing compounds, 407
 Conductive ion channel, 163
 Congenital stationary night blindness (CSNB2), 21
 Constitutive exons, 221
 Crayfish neuromuscular junction, 178
 CREB phosphorylation, 20
 Cryo-electron microscopy, 140
 Current-clamped DRG neuron, 90
 Cysteine string protein (CSP), 226
 Cytoplasmic hydrophobic domains, 319
 Cytoplasmic proteins, 140
 Cytosolic A-kinase-anchoring protein, 325
 Cytosolic channel partners, 68
 anchoring of, 68
 Cytosolic proteins, 282
- DAP amplitudes, 198
 Dehydroabiatic acid, 424
 Dentate gyrus granule cells, 333
 Deoxycarnitine ester prodrug, 428
 Diabetic neurons, 84
 Diabetic neuropathy, 47, 84
 Dihydropyridine-sensitive calcium channels, 18
 Dinucleotide splicing recognition sequences, 233
 Disulfide bond, 7
 DNA binding protein, 346
 DNA databases, 199
 DNA fragmentation, 430
 DNA plasmid, 432
 DNP, 176
 Dopamine receptor-induced inhibition, 304
 Dorsal root ganglion (DRG), 38, 68, 69, 304, 367
 Double-label immunofluorescence studies, 398
 Downstream enzymes, 155
 DRG neurons, 42, 45, 46, 69, 70, 71, 73, 74, 75, 76, 78, 80, 81, 82, 85, 88, 89, 90, 375, 376, 398, 408
- DRG/spinal nerves, 367
 Drosophila discs, 143
 Drosophila embryonic neurons, 258
 Drosophila melanogaster, 133, 344
 Drug binding site, 6, 236
 Drug interaction, 7
 Drug targets, 443
- EAG cells, 110
 EAG channels, 111
 Ectodomain-directed antibodies, 141
 EF-hand proteins, 358
 Electrical excitability, 127
 Electron micrographs, 180
 Electron microscopy (EM), 349
 Electron transport inhibitor, 176
 Electrophysiological defects, 21
 EM structure, 349
 Endogenous death channels, 165
 Endogenous promoter, 9
 Endoplasmic retention signal (CVLF), 331
 Endoplasmic reticulum (ER) membrane, 220, 328
 Energy-dependent processes, 174
 Epilepsy, 333
 Epilepsy/bipolar disorder, 430
 Epileptogenic activity, 17
 Episodic ataxia, 144
 Epithelial Na⁺ channels, 258
 Erectile dysfunction (ED), 430
 ERR motifs, 136, 141
 ERR receptor protein, 136
 EST database, 225
 Estrogen response elements (ERE), 328
 sites, 329
 Ethosuximide, 44
 Excitation-contraction coupling, 7
 organization of, 7
 Exogenous factors, 73
 Experimental autoimmune encephalomyelitis (EAE), 71
 Expression systems, 201, 202, 259
 Extracellular linker, 231
- Flash Luminescence, 452
 Fluorescence polarization (FP) technique, 446
 Fluorescence resonance energytransfer (FRET)-based dyes, 451

- Fluorescent dye assays, 449
 Food and Drug Administration (FDA), 40, 374, 375
 Fox binding sequence, 236
 FRET technologies, 377
 G-proteins, 402
 G-protein activation, 229
 G-protein-coupled receptor (GPCR), 291, 396
 G-protein-coupled receptors, 396
 G-protein-mediated inhibition, 230
 G-protein mechanisms, 301
 GABA transaminase, 51
 Gene transcription, 35
 Gene transcription activity, 9
 Genetically epilepsy-prone rats (GEPR), 52
 Genome sequences, 226
 GFP, 297
 GK domain, 7
 Glioma cells, 105, 107, 111, 116
 cell lines, 114
 cell proliferation, 108
 Glucose tolerance, 21
 Glutamate-threonine (ET), 232
 Glutamic acid residue, 6
 Glycolytic pathway, 159
 Golgi apparatus, 331
 GPCR activation, 401
 GYG pore sequence, 200
- HEK cells, 46, 206, 208, 424
 HERG gene, 283
 Heterologous expression systems, 136, 137, 140
 Heterologous systems, 325
 Heteromeric channel complexes, 133
 Hexokinase sites, 160
 High-affinity subtype-selective T-type channel blockers, 44
 High-dose groups, 432
 High-frequency discharge, 199, 209
 High-frequency signals, 230
 High-throughput screening (HTS), 444
 High voltage activated (HVA) Ca_v channels, 4, 35, 36
 biophysical properties, 36
 Higher order sensory neurons, 78
 Hippocampal neurons, 254
 Homozygous lethality, 399
- HTS approaches, 445
 HUGO Gene Nomenclature Committee (HGNC), 395
 Human embryonic kidney (HEK), 424
 cell line, 206, 257
 Human ether-a-go-go-related (HERG), 282, 283, 446, 460–462
 Human genome sequence, 224
 Human nervous system, 233
 HVA channels, 4, 35, 45
 HVA, *see* High voltage activated
 Hypoxia-inducible factor (HIF) transcription factor, 255
 Hydrophilic pathway, 12
 Hydrophilic pores, 279
 Hydrophilic segments, 157
 Hydrophobic residues, 351
 Hyperexcitable mutant gene, 344
 Hypoglossal motoneurons, 254
 Hypoxia-induced cellular pathways, 268
- Idiopathic generalized epilepsies (IGEs), 47
 ICA-27243, 410, 412
 IK channels, 261
 Immunocytochemical analysis, 397
 Immunohistochemical analysis, 132
In situ hybridization, 42, 51, 79, 132, 200
In vivo phosphorylation sites, 139
 Inflammation-induced pain, 80
 symptoms, 80
 Inflammatory hyperalgesia, 87
 Inflammatory mediators, 83
 Inflammatory models, 380
 SNL, 380
 Inflammatory pain, 36, 38, 39, 82, 377, 409
 Influx pathway, 174
 Inherited disorders, 20
 Inherited erythromelalgia, 89
 Inhibitory components, 403
 Injury-mediated effects, 73
 Inner membrane channel, 181
 Inner membrane physiology, 170
 Insulin secretion, 21
 Integral membrane proteins, 7
 Intermediate-conductance channels, 202, 261
 Intermembrane space proteins, 161
 cytochrome, 161
 Intracellular calcium homeostasis, 177
 Intracellular messengers, 280

- Intracellular organelle membranes, 162
- Ion channels, 105, 127, 155, 171, 196, 252, 264, 279, 283, 284, 291, 443, 447
 activity, 162
 auxiliary subunits, 140
 drugs, 443
 expression, 105
 HTS technologies, 445
 modulation, 286
 modulators, 445
 proteins, 447
 role of, 105, 252
 significance of, 286
- Ion conducting pathway, 158
- Ion flux assays, 447
- Ionic conductance pathway, 133
- Ionic exchangers, 251
- Isoform-selective drug screening, 237
- Isoform-specific antibodies, 74, 235
- Isoform-specific interactions, 231
- KATP channel, 204, 263, 264
- K_{Na} channels, 194, 195, 196, 197, 199, 200, 203, 204, 205, 209, 210
 pharmacology of, 205
- K_{Na} currents, 195
- K_{Na} inhibition, 206
- K_{Na} modulators, 208
- König's polyanion, 158
- KCNQ channel(s), 281, 293, 395
- K⁺ channel, 47, 105, 107, 108, 193, 196–200, 204, 206, 259–268, 281, 282, 286, 393, 395, 411
 involvement of, 108
 modulation of, 292–295, 302, 304, 344
 types, 291, 292
- K⁺ channel-associated protein (KChAP), 281
- K⁺ channel interacting proteins (KChIPs), 281, 344–358, 453
- K⁺ channel modulators, 206
 K_v channels, 345
- K_v1 channels, 129, 132, 143
 activation of, 132
- K_v4 channels, 344–358, 453
- K_v7 channels, 206, 292–307, 393–412
- L-type antagonists, 21
 molecular properties of, 129
- L-type calcium channels, 7, 10, 12, 18, 19, 22, 220
 activity, 8
 antagonists, 16
 physiological and pharmacological expression, 8
- L-type channel genes, 20
 diltiazem, 21
 nifedipine, 21
- L-type VGCC inhibitors, 117
- Lidocaine, 374
- Lidocaine drug, 366
- Ligand binding assays, 445, 446
- Ligand-gated ion channels, 195, 280
- Ligand-receptor interactions, 396
- Lipid membranes, 165
- Long-QT syndrome (LQTS), 283
- Long-term depression (LTD), 14
- Long-term potentiation (LTP), 14, 170
- Loss-of-function mutations, *see* Night blindness
- Low-frequency impulses, 365
- Low-voltage activated (LVA) channels, 116
- LTP, *see* Long-term potentiation
- LVA channels, 46, 116
- LVA, *see* Low voltage activated
- Lysine residues, 6
- M-channels, 291, 295
 activity, 292
 subunits, 299
- M-current suppression, 307
- MAC activity, 165
- Madin-Darby canine kidney (MDCK), 330
- Magnetic resonance imaging, 411
- Malignant transformation, 107
- Mammalian genes, 282
- Mammalian genomes, 223
- Mammalian neurons, 254
- Mammalian smooth muscles, 423
- MCC, 174, 176
- Medial nucleus of the trapezoid body (MNTB), 197, 199
 neurons, 209
- Membrane-delimited preparations, 260
- Membrane-spanning d component, 7
- Membrane-spanning domains, 357
- Membrane-targeted peptides, 297
- Membrane depolarizations, 255

- Membrane proteins, 252
- Metabolites, 157
 - ADP, 157
 - ATP, 157
- Metabolite fluxes, 171
- Missense mutations, 21, 50
- Mitochondrial ATP, 172
 - regulation of, 172
- Mitochondrial ATP release, 178
- Mitochondrial bioenergetics, 178
- Mitochondrial conductance, 180
- Mitochondrial depolarization, 170
- Mitochondrial dysfunction, 267
- Mitochondrial ion channel, 177, 180
- Mitochondrial membrane, 155, 163, 180, 182
 - activity, 181
 - component, 165
 - inner membrane, 155
 - outer membrane, 155
 - potential, 174
- Mitochondrial metabolism, 160
- Mitochondrial permeability transition pore (mPTP), 173, 174
- Mitochondrial respiration, 176
- Mitochondrial signal, 177
- Mitochondrial targeting proteins, 178
- Mitogen-activated protein kinase (MAPK) pathway, 14
- Mitogenic signals, 110
- Modular adapter proteins, 13
- Modulatory proteins, 284
- Molecular machine, 220
- Motogenic signals, 110
- MPTP components, 181
 - ANT, 181
 - BCL-2 family, 181
 - BCL-xL, 181
 - VDAC, 181
- MRNA polyadenylation signals, 320
- MRNA processing, 320
- Multicellular organisms, 169
- Muscarinic depression, 297

- Na⁺ channel-blocking drugs, 366
- Na⁺ channel blockers, 257, 376, 378
- Na⁺ channel density, 258
- Na⁺ channel expression, 116
- Na⁺ current, 256
- Na⁺ dependent DAPs, 209

- N*-ethylmaleimide (NEM), 403
- N*-linked glycosylation (NLG), 138
 - site, 134
- N*-terminal domain, 346
- N*-terminal hydrophobic peptide, 349, 352
- N*-terminal inactivation peptide, 352
- N*-terminal residue, 139
- N*-terminal sequence, 204
- N*-terminus complex, 349
- N*-type channels, 13, 41, 42, 53, 300, 302
 - role of, 41
- N*-type immunoreactivity, 38
- Neonatal neurons, 258
- Nerve growth factor (NGF), 116
- Nerve transection, 72
- Nervous system, 9, 219, 222
- Neurodegenerative diseases, 283
- Neurodegenerative disorders, 209, 268
 - stroke, 209, 268
 - trauma, 268
- Neuroendocrine cells, 8
- Neurological deficits, 22
- Neurological disorder, 144
 - epilepsy, 144
- Neuromodulation, 286
- Neuronal disturbances, 3
- Neuronal calcium sensor (NCS), 344
- Neuronal disorders, 20
- Neuronal excitability, 208
 - regulation of, 208
- Neuronal L-type voltage-gated calcium channel (NLTCC), 4
- Neuronal pathway, 14
- Neuronal sodium channels, 69
 - Na_v 1.6-1.9, 69
- Neuropathic pain, 41, 68, 73, 237, 376, 407, 408
- Neuropathic pain model, 46
- Neuropathy-induced thermal hyperalgesia, 44, 46
- Neuropathy models, 44
- Neurotransmitter-containing vesicles, 182
- Neurotransmitter systems, 20
- Neurotrophic factors, 73
- Nicotinamide adenine dinucleotide phosphate, 140
- Nicotinic acetylcholine receptors (nAChRs), 18
- Night blindness, 8

- NLTCs, 13, 15, 17, 18, 19
 antagonists of, 15, 18
 isoforms of, 13
 role of, 13
 NMDA receptors, 38, 220, 267, 281
 Nonradiometric flux assays, 447, 448
 Nonneuronal cells, 132
 NP encoding exon, 231
- Obsessive-compulsive disorder, 45
 Oculomotor nuclei, 201
 Oligosaccharide-processing enzymes, 138
 Optical techniques, 174
 Oscillatory network, 48
 Oxidative metabolism, 178
 Oxidative phosphorylation, 155, 156
 Oxidizing agent DTNB, 46
 Oxidoreductase active site, 140
 Oxidoreductase-like proteins, 140
 Oxygen deprivation, 251
- Paralogous genes, 130
 Paroxysmal movement disorder, 331, 333
 Paw-withdrawal latencies (PWLs), 46
 Paw-withdrawal test, 44
 PCREB signaling, 9
 PDZ domain, 204
 PDZ-domain sequence, 200
 Peptide toxins, 206
 Peripheral nervous systems, 8
 Peripheral axons, 76
 regenerative response, 76
 Peripheral injury, 87
 Peripheral nervous system, 3, 38, 407
 Peripheral neuropathies, 88
 Peripheral tissues, 261
 Permeability transition pore, 174
 PIP₂, 296–299, 302, 306–307, 396, 401–402
 Pharmacological agents, 205, 376
 PKA activation, 139
 PKA phosphorylation, 324
 PKC blockers, 256
 Planar patch-clamp systems, 455
 Plasma membrane, 67
 Plasma membrane channels, 180
 Plasma membrane exchangers, 252
 Plasma membrane subdomains, 143
 PLC activation, 295
 PNS tissues, 69
- Polar drugs, 12
 Polarized epithelial cells, 142
 Polyclonal antibodies, 51
 Pore-forming components, 396
 Pore-forming HVA, 36
 Pore-forming subunits, 177
 Pore-localized ERR signal, 136
 Postmitotic cells, 107
 Postoperative pain model, 45
 Postsynaptic cell, 181
 Postsynaptic laminins, 232
 Posttranslational modifications, 68, 138,
 280, 320, 324
 Potassium (K⁺) channels, 430, 443
 inhibitors, 444
 Pre-mRNA splicing, 219
 Preganglionic nerve terminals, 40
 Preoptic nucleus, 200
 Presynaptic calcium channels, 232
 Presynaptic nerve terminals, 233
 Presynaptic proteins, 233
 Proapoptotic mitochondrial
 factors, 183
 Proapoptotic molecules, 163, 182, 183
 Bax, 182
 DNBCL-xL, 182
 Progenitor cells, 107
 Programmed cell death, 155, 160, 167
 Proliferating tumors, 106
 astrocytomas, 106
 glioblastomas, 106
 Proline-rich tyrosine kinase, 324
 Promoter-regulatory motifs, 326
 Protein-conducting channels, 174
 Protein-mediated inhibition, 229
 Protein-protein interactions, 128, 142
 Protein binding domain, 221
 Protein expression, 9
 Protein interaction, 393
 Protein kinases, 138, 200, 281, 303
 Protein phosphorylation, 393
 Protein translocators, 177
 Proteomic analysis, 268
 Proximal dendrites, 9
 P-type channel, 236
 inactivation, 232
 PTX-treated SCG neurons, 302
 Pulmonary arteries, 264
 Purkinje cells, 232

- Purkinje neurons, 332
- Pyramidal neurons, 255

- Quinidine, 206, 207

- RCK domains, 204
- Reactive oxygen species (ROS), 175
- Receptor-mediated inhibition, 402
- Receptor-mediated mechanisms, 394
- Receptor site organization, 4
- Recombinant BCL-xL protein, 168
- Regulatory proteins, 222
- Repressor proteins, 220
- Retinal glial cells, 106
 - retigabine, 404, 406–412
- RIM binding protein, 226
- RNA binding proteins, 220, 221, 236
- RNA expression, 51
- RNA processing, 219
- RT-PCR analysis/techniques, 234, 398
- Ryanodine receptor, 173

- Scaffolding proteins, 283
- Sciatic nerve, 78
 - ligation, 374
 - neuromas, 77
- Second-order neurons, 37
- Semichronic pain syndromes, 407
- Sensory responses, 408
- Serine phosphorylation sites, 139
- Serotonin-modulated glutamate, 130
- Signaling complexes, 286
- Signaling pathways, 36, 162, 292, 299
- Single-cell analysis, 222
- Single-cell reverse transcriptase-polymerase chain reaction (RT-PCR), 222
- Single-channel conductance, 202
- Single nucleotide polymorphisms (SNPs), 50
- Sinusoidal currents, 197
- Site-directed mutagenesis, 157
- Six transmembrane segments, 68
- Size exclusion chromatography, 168
- SK channels, 260
- Skeletal muscles, 259
- Slack channels, 202, 203
- Slo1, 194, 196, 203, 206, 318–334, 393
- Slo2, 193, 200, 203, 319–320
- Slack currents, 208

- Slo3, 320
- Slick-transfected CHO cells, 202
- Slo interacting protein 1 (SLIP1), 281
- Slo binding protein (Slob), 281–282, 284–285
- Small-and intermediate-conductance K_{Ca} channels, 196
- Small-molecule blockers, 366, 382
- Small interfering RNA (siRNA), 41
- Smooth muscles, 259
- Sodium-activated potassium current, 194
- Sodium channel blockers, 87, 91
- Sodium channels, 67, 68, 72, 76, 91
 - dysregulation of, 68, 78, 84, 87
 - expression of, 68, 69, 78, 91
 - isoforms, 69, 91
 - transcript, 84
- Sodium ions, 67
- Somatosensory pathway, 42
- Spared nerve injury (SNI), 72
- Spinal cord injury (SCI), 86, 87
- Spinal cord neurons, 258
- Spinal nerve ligation (SNL), 72
- Spliced exons, 220
- Splicing enhancers, 220
- Splicing factors, 236
- Starvation-induced death, 284
- State-dependent actions, 12
- Superior cervical ganglion (SCG), 292
 - neurons, 401
- Supramolecular protein complexes, 128
- Susac's syndrome, 19
- SWD discharges, 49
- Swept field confocal (SFC) system, 305
- Sympathetic nerve dysfunction, 41
- Sympathetic neurons, 304, 306
- Synaptic depression, 182, 282
- Synaptic machinery, 226
- Synaptic transmission, 38, 178

- T-type calcium channels, 37, 42, 44, 45, 46, 47, 48, 50, 51, 52
 - blockers, 42, 44, 47
 - currents, 49
 - inhibitor, 117
 - involvement of, 117
 - isoform, 48
 - expression of, 42
 - role, 42, 51

- Tail-flick test, 44
- TC neuron, 43
- Tetramerization domain, 345
- Thalamic reticular neurons, 48
- Thalamocortical (TC) neurons, 43
- Therapeutic agents, 206
- Therapeutic index, 237
- Thermal hyperalgesia, 45
- Time-dependent analgesia, 46
- Time-dependent hyperalgesia, 46
- Trafficking signal, 135
- Trans-membrane domains (TMD), 300
- Transient subconductance levels, 195
- Transmembrane domains, 325
- Transmembrane reporter proteins, 142
- Transmembrane voltage, 400
- Tricyclic antidepressants, 381
- TTX-resistant currents, 74, 79
- Turtle neurons, 258
- Two-hybrid screens, 281
- Tyrosine kinases, 307
- Tyrosine phosphatase inhibitors, 139
- Tyrosine phosphorylation, 139

- Untranslated region (UTR), 320

- Variance-mean analysis, 195
- Ventilation/perfusion ratios, 252
- Ventral posterolateral (VPL), 87
 - thalamocortical neurons, 43
- Ventricular myocytes, 257
- Vesicle pools, 179, 182
- Vestibular nuclei, 201
- VGCC expression, 117
- VGCC inhibitors, 116, 117
- VGCCs inhibition, 117
- VIPR technologies, 377
- Visceral organs, 83
 - inflammation of, 83
- Voltage-activated calcium channels, 427
- Voltage-clamp techniques, 403
- Voltage-dependent anion channel (VDAC)
 - 156, 158, 264
 - channel, 160, 167
 - dimerization, 167
 - genes, 169
 - inhibitor, 164
 - interacting proteins, 167
 - oligomerization, 167
 - protein, 157
- Voltage-dependent channels, 264
- Voltage-dependent currents, 114
- Voltage-dependent potassium (K_v) channels, 127, 343
- Voltage-dependent sodium (Na^+) channels, 365
- Voltage-gated calcium (Ca^{2+}) channel, 5, 6
 - schematic representation, 5
- Voltage-gated calcium channels, 4, 9, 20, 223, 231, 237
 - HVA, 4
 - LVA, 4
- Voltage-gated ion channels, 4, 155, 157, 193, 195, 291, 412
- Voltage-gated sodium currents, 70
- Voltage-independent inhibition, 230
- Voltage-independent pathways, 229
- Voltage-sensing domains, 345
- Voltage-sensitive calcium channels, 255
- Voltage sensor region, 345

- Water-filled channels, 177
- Western blot analysis, 200
- Whole-cell currents, 113, 202
- Whole-cell levels, 303
- Whole-cell voltage-clamp, 400
- Willing/reluctant model, 300
- Women's Angiographic Vitamin and Estrogen (WAVE) 333

- Xenopus oocytes*, 202, 203, 208

- Zinc pirithione, 405

